Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
This grant supports research to optimize and advance genomic and biologic therapies for Alzheimer’s-related dementias, from preclinical development through early clinical evaluation.
Funder: National Institutes of Health
Due Dates (Anticipated): November 2026 (Full application deadline, projected)
Funding Amounts: Estimated total program funding: $6,000,000; ~3 awards expected; award size/duration not specified.
Summary: Supports translational research to optimize and develop genomic and biologic therapeutic candidates for Alzheimer’s Disease-Related Dementias (ADRD).
Key Information: This is a forecasted opportunity; applications are not yet being solicited.
Description
This forecasted opportunity from the National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (NINDS), aims to support research projects focused on the optimization and translational development of genomic and biologic therapies for Alzheimer’s Disease-Related Dementias (ADRD). The initiative seeks to accelerate the development of disease-modifying treatments for dementias such as frontotemporal degeneration (FTD), Lewy body dementia (LBD), and vascular contributions to cognitive impairment and dementia (VCID).
Eligible projects may span the translational pipeline, including:
- Optimization of therapeutic design and manufacturability
- Establishment of pharmacology, toxicology, biodistribution, and in vivo efficacy
- Compilation of data necessary for regulatory submissions (e.g., IND)
- Early clinical evaluation, including first-in-human (FIH) studies where appropriate
This funding mechanism is a cooperative agreement (U01), and the call is aligned with priorities set by the ADRD Summits. Notice is provided in advance to allow applicants time to develop collaborations and competitive proposals.
